Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 175
Filtrar
1.
Mol Nutr Food Res ; 66(22): e2200177, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-36068654

RESUMEN

SCOPE: Milk fat globule membrane (MFGM) is an essential component of milk. Bovine MFGM (bMFGM) has been shown to support cognitive development and increase relative concentrations of serum phospholipids. This study investigates bioavailability of bMFGM components after oral administration in two preclinical models to explore whether dietary bMFGM induces parallel changes to plasma and brain lipidomes. METHODS AND RESULTS: Transgenic APOE*3.Leiden mice (n = 18 per group) and Sprague-Dawley rats (n = 12 per group) are fed bMFGM-enriched (MFGM+) or Control diet, followed by phospholipid profile-determination in plasma, hippocampus, and prefrontal cortex tissue by targeted mass spectrometry. Multivariate analysis of lipidomic profiles demonstrates a separation between MFGM+ and Control plasma across rodents. In plasma, sphingomyelins contributed the most to the separation of lipid patterns among both models, where three sphingomyelins (d18:1/14:0, d18:1/23:0, d18:1/23:1[9Z]) are consistently higher in the circulation of MFGM+ groups. A similar trend is observed in rat prefrontal cortex, although no significant separation of the brain lipidome is demonstrated. CONCLUSION: bMFGM-enriched diet alters plasma phospholipid composition in rodents, predominantly increasing sphingomyelin levels in the systemic circulation with similar, but non-significant, trends in central brain regions. These changes may contribute to the beneficial effects of bMFGM on neurodevelopment during early life.


Asunto(s)
Suplementos Dietéticos , Glucolípidos , Glicoproteínas , Gotas Lipídicas , Lipidómica , Animales , Ratones , Ratas , Encéfalo , Gotas Lipídicas/química , Fosfolípidos/farmacología , Ratas Sprague-Dawley , Esfingomielinas/farmacología , Glicoproteínas/administración & dosificación , Glucolípidos/administración & dosificación
2.
J Sci Food Agric ; 102(3): 908-919, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34235749

RESUMEN

BACKGROUND: Rhamnolipids (RLS), well known as glycolipid biosurfactants, display low toxicity, high biodegradability, and strong antibacterial properties. This study was carried out to evaluate the use of RLS supplementation as a substitute for antibiotics, and particularly to evaluate its effects on growth performance, immunity, intestinal barrier function, and metabolome composition in broilers. RESULTS: The RLS treatment improved the growth performance, immunity, and intestinal barrier function in broilers. The 16S rRNA sequencing revealed that the genus Alistipes was the dominant genus in broilers treated by RLS. An ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS)-based metabolomic analysis indicated that the sphingolipid metabolism, glycine, serine, and threonine metabolism, the gycerophospholipid metabolism, and the tryptophan metabolism were changed in broilers that were treated with RLS. CONCLUSION: l-Tryptophan may be the medium for RLS to regulate the growth and physiological metabolism. Rhamnolipids can be used as a potential alternative to antibiotics, with similar functions to antibiotics in the diet of broilers. The optimal level of supplemented RLS in the diet was 1000 mg kg-1 . © 2021 Society of Chemical Industry.


Asunto(s)
Pollos/crecimiento & desarrollo , Pollos/inmunología , Glucolípidos/administración & dosificación , Intestinos/inmunología , Metaboloma/efectos de los fármacos , Alimentación Animal/análisis , Animales , Bacterias/clasificación , Bacterias/efectos de los fármacos , Bacterias/genética , Bacterias/aislamiento & purificación , Pollos/metabolismo , Pollos/microbiología , Suplementos Dietéticos/análisis , Microbioma Gastrointestinal/efectos de los fármacos , Intestinos/metabolismo , Intestinos/microbiología , Metabolómica
3.
Blood ; 139(8): 1135-1146, 2022 02 24.
Artículo en Inglés | MEDLINE | ID: mdl-34543383

RESUMEN

Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A phase 1/2 study evaluated the safety, tolerability, and antileukemic activity of uproleselan (5-20 mg/kg) with MEC (mitoxantrone, etoposide, and cytarabine) among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Among the first 19 patients, no dose-limiting toxicities were observed. The recommended phase 2 dose (RP2D) was 10 mg/kg twice daily. An additional 47 patients with R/R AML were treated with uproleselan at the RP2D plus MEC. At the RP2D, the remission rate (complete response [CR]/CR with incomplete count recovery [CRi]) was 41% (CR, 35%), and the median overall survival (OS) was 8.8 months. In a separate cohort, 25 newly diagnosed patients age ≥60 years received uproleselan at the RP2D plus cytarabine and idarubicin (7 + 3). In these frontline patients, the CR/CRi rate was 72% (CR, 52%), and the median OS was 12.6 months. The addition of uproleselan was associated with low rates of oral mucositis. E-selectin ligand expression on leukemic blasts was higher in patients with relapsed vs primary refractory AML and in newly diagnosed older patients with high-risk cytogenetics and secondary AML. In the R/R cohort, E-selectin expression >10% was associated with a higher response rate and improved survival. The addition of uproleselan to chemotherapy was well tolerated, with high remission rates, low induction mortality, and low rates of mucositis, providing a strong rationale for phase 3 randomized confirmatory studies. This trial was registered at www.clinicaltrials.gov as #NCT02306291.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Glucolípidos/administración & dosificación , Leucemia Mieloide Aguda , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Citarabina/administración & dosificación , Citarabina/efectos adversos , Supervivencia sin Enfermedad , Etopósido/administración & dosificación , Etopósido/efectos adversos , Femenino , Glucolípidos/efectos adversos , Humanos , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/mortalidad , Masculino , Persona de Mediana Edad , Mitoxantrona/administración & dosificación , Mitoxantrona/efectos adversos , Tasa de Supervivencia
4.
Nutrients ; 13(12)2021 Nov 26.
Artículo en Inglés | MEDLINE | ID: mdl-34959820

RESUMEN

Brown adipose tissue (BAT) activation is associated with increased energy expenditure by inducing non-shivering thermogenesis. The ingestion of a milk fat globule membrane (MFGM) supplement and a high calorie diet are reported gateways into BAT activation. However, little is known about the effect of the MFGM and high calorie diets on BAT volume. To gain insight into this, mice were maintained on a high-fat (HF) or low-fat (LF) diet in conjunction with either full-cream (FC) or skim bovine dairy milk (BDM). After being maintained on their respective diets for 13 weeks, their body composition, including BAT volume, was measured using X-ray microtomography. A high calorie diet resulted in an increase in the BAT volume and mice consuming an HF diet in conjunction with FC BDM had a significantly greater BAT volume than all the other groups. Conversely, mice consuming an HF diet in addition to skim milk had a lower BAT volume compared to the HF control. The data presented suggest that the consumption of a high calorie diet in conjunction with FC BDM increases the BAT volume in wild-type mice. This study may provide valuable insight into future studies investigating BAT volume and BAT activity in relation to environmental factors, including diet.


Asunto(s)
Tejido Adiposo Pardo/efectos de los fármacos , Composición Corporal/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Leche/química , Animales , Bovinos , Dieta con Restricción de Grasas/métodos , Dieta Alta en Grasa/métodos , Gotas Lipídicas , Lípidos/administración & dosificación , Ratones , Termogénesis/efectos de los fármacos
5.
Front Immunol ; 12: 727300, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34887849

RESUMEN

Upon infection with Mycobacterium tuberculosis (Mtb) the host immune response might clear the bacteria, control its growth leading to latent tuberculosis (LTB), or fail to control its growth resulting in active TB (ATB). There is however no clear understanding of the features underlying a more or less effective response. Mtb glycolipids are abundant in the bacterial cell envelope and modulate the immune response to Mtb, but the patterns of response to glycolipids are still underexplored. To identify the CD45+ leukocyte activation landscape induced by Mtb glycolipids in peripheral blood of ATB and LTB, we performed a detailed assessment of the immune response of PBMCs to the Mtb glycolipids lipoarabinomannan (LAM) and its biosynthetic precursor phosphatidyl-inositol mannoside (PIM), and purified-protein derivate (PPD). At 24 h of stimulation, cell profiling and secretome analysis was done using mass cytometry and high-multiplex immunoassay. PIM induced a diverse cytokine response, mainly affecting antigen-presenting cells to produce both pro-inflammatory and anti-inflammatory cytokines, but not IFN-γ, contrasting with PPD that was a strong inducer of IFN-γ. The effect of PIM on the antigen-presenting cells was partly TLR2-dependent. Expansion of monocyte subsets in response to PIM or LAM was reduced primarily in LTB as compared to healthy controls, suggesting a hyporesponsive/tolerance pattern derived from Mtb infection.


Asunto(s)
Tuberculosis Latente/inmunología , Tuberculosis/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Antígenos Bacterianos/administración & dosificación , Antígenos Bacterianos/inmunología , Linfocitos B/clasificación , Linfocitos B/inmunología , Estudios de Casos y Controles , Estudios de Cohortes , Citocinas/biosíntesis , Femenino , Glucolípidos/administración & dosificación , Glucolípidos/inmunología , Humanos , Técnicas In Vitro , Células Asesinas Naturales/inmunología , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/inmunología , Células Mieloides/inmunología , Fosfatidilinositoles/administración & dosificación , Fosfatidilinositoles/inmunología , Estudios Prospectivos , Linfocitos T/clasificación , Linfocitos T/inmunología , Receptor Toll-Like 2/inmunología , Tuberculina/administración & dosificación , Tuberculina/inmunología , Adulto Joven
6.
Nutrients ; 13(12)2021 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-34960093

RESUMEN

Inclusion of bovine-derived milk fat globule membrane (bMFGM) or bMFGM components in infant formulas (IFs) may support healthy brain development. This double-blind, prospective trial evaluated growth, tolerance, and iron status in infants receiving added bMFGM and modified protein, iron, and arachidonic acid (ARA) concentrations in IF. Healthy term infants were randomized to: control (marketed, routine cow's milk-based IF/100 kcal: 2.1 g protein, 1.8 mg iron, 34 mg ARA) or INV-MFGM (investigational cow's milk-based IF/100 kcal: 1.9 g protein, 1.2 mg iron, 25 mg ARA and whey protein-lipid concentrate, 5 g/L (source of bMFGM)). Anthropometrics, stool characteristics, fussiness, and gassiness through day 365 and blood markers of iron status at day 365 were evaluated. The primary outcome was rate of weight gain from 14-120 days of age. Of 373 infants enrolled (control: 191, INV-MFGM: 182), 275 completed the study (control: 141; INV-MFGM: 134). No group differences in growth rate (g/day) from day 14-120 or study discontinuation were detected. Few group differences in growth or parent-reported fussiness, gassiness, or stool characteristics were detected. No group differences were detected in hemoglobin, hematocrit, or incidence of anemia. In healthy term infants, bMFGM and modified protein, iron, and ARA concentrations in a cow's milk-based IF were well-tolerated, associated with adequate growth throughout the first year of life, and supported normal iron status at one year of age.


Asunto(s)
Desarrollo Infantil/fisiología , Alimentos Fortificados , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Fórmulas Infantiles , Fenómenos Fisiológicos Nutricionales del Lactante , Hierro de la Dieta/administración & dosificación , Hierro/metabolismo , Factores de Edad , Femenino , Humanos , Lactante , Recién Nacido , Gotas Lipídicas , Masculino
7.
Nat Commun ; 12(1): 7264, 2021 12 14.
Artículo en Inglés | MEDLINE | ID: mdl-34907171

RESUMEN

Antibodies targeting costimulatory receptors of T cells have been developed for the activation of T cell immunity in cancer immunotherapy. However, costimulatory molecule expression is often lacking in tumor-infiltrating immune cells, which can impede antibody-mediated immunotherapy. Here, we hypothesize that delivery of costimulatory receptor mRNA to tumor-infiltrating T cells will enhance the antitumor effects of antibodies. We first design a library of biomimetic nanoparticles and find that phospholipid nanoparticles (PL1) effectively deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Then, we demonstrate that the combination of PL1-OX40 mRNA and anti-OX40 antibody exhibits significantly improved antitumor activity compared to anti-OX40 antibody alone in multiple tumor models. This treatment regimen results in a 60% complete response rate in the A20 tumor model, with these mice being resistant to rechallenge by A20 tumor cells. Additionally, the combination of PL1-OX40 mRNA and anti-OX40 antibody significantly boosts the antitumor immune response to anti-PD-1 + anti-CTLA-4 antibodies in the B16F10 tumor model. This study supports the concept of delivering mRNA encoding costimulatory receptors in combination with the corresponding agonistic antibody as a strategy to enhance cancer immunotherapy.


Asunto(s)
Materiales Biomiméticos/administración & dosificación , Inmunoterapia/métodos , Linfocitos Infiltrantes de Tumor/inmunología , Nanopartículas/administración & dosificación , ARN Mensajero/administración & dosificación , Linfocitos T/inmunología , Animales , Materiales Biomiméticos/química , Sistemas de Liberación de Medicamentos , Glucolípidos/administración & dosificación , Glucolípidos/química , Linfocitos Infiltrantes de Tumor/metabolismo , Ratones , Nanopartículas/química , Neoplasias Experimentales/inmunología , Neoplasias Experimentales/terapia , Fosfolípidos/administración & dosificación , Fosfolípidos/química , ARN Mensajero/química , Receptores OX40/antagonistas & inhibidores , Receptores OX40/genética , Receptores OX40/inmunología , Receptores OX40/metabolismo , Linfocitos T/metabolismo , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/antagonistas & inhibidores , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/genética , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/metabolismo
8.
Nutrients ; 13(9)2021 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-34578827

RESUMEN

The human milk fat globule membrane (MFGM) contains important lipids for growing infants. Anthropometric measurements, milk samples, and infant milk intake were collected in a cohort of eleven healthy mother-infant dyads during exclusive breastfeeding from birth to six months. One hundred and sixty-six MFGM lipids were analysed using liquid chromatography-mass spectrometry, and the infant intake was calculated. The concentrations and intake were compared and associations between infant intake and growth characteristics explored. The lipid concentrations and infant intake varied widely between mother-infant dyads and between months one and three. The infant intake for many species displayed positive correlations with infant growth, particularly phospholipid species. The high variation in lipid intake is likely an important factor in infant growth, with strong correlations identified between the intake of many MFGM lipids and infant head circumference and weight. This study highlights the need for intake measurements and inclusion in cohort studies to elucidate the role of the human milk lipidome in infant growth and development.


Asunto(s)
Lactancia Materna/estadística & datos numéricos , Glucolípidos/administración & dosificación , Glucolípidos/análisis , Glicoproteínas/administración & dosificación , Glicoproteínas/análisis , Leche Humana/química , Adulto , Cromatografía Liquida , Femenino , Humanos , Lactante , Gotas Lipídicas , Estudios Longitudinales , Masculino , Espectrometría de Masas , Valores de Referencia , Australia Occidental
9.
Nutrients ; 13(7)2021 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-34371820

RESUMEN

Morphological changes in neuromuscular junctions (NMJs), which are synapses formed between α-motor neurons and skeletal muscle fibers, are considered to be important in age-related motor dysfunction. We have previously shown that the intake of dietary milk fat globule membrane (MFGM) combined with exercise attenuates age-related NMJ alterations in the early phase of aging. However, it is unclear whether the effect of MFGM with exercise on age-related NMJ alterations persists into old age, and whether intervention from old age is still effective when age-related changes in NMJs have already occurred. In this study, 6- or 18-month-old mice were treated with a 1% MFGM diet and daily running wheel exercise until 23 or 24 months of age, respectively. MFGM treatment with exercise was effective in suppressing the progression of age-related NMJ alterations in old age, and even after age-related changes in NMJs had already occurred. Moreover, the effect of MFGM intake with exercise was not restricted to NMJs but extended to the structure and function of peripheral nerves. This study demonstrates that MFGM intake with exercise may be a novel approach for improving motor function in the elderly by suppressing age-related NMJ alterations.


Asunto(s)
Envejecimiento/fisiología , Fenómenos Fisiológicos Nutricionales de los Animales/efectos de los fármacos , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Unión Neuromuscular/efectos de los fármacos , Condicionamiento Físico Animal/fisiología , Animales , Suplementos Dietéticos , Gotas Lipídicas , Ratones , Neuronas Motoras/efectos de los fármacos , Fibras Musculares Esqueléticas/efectos de los fármacos , Sinapsis/efectos de los fármacos
10.
Eur J Pharm Biopharm ; 165: 293-305, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34044110

RESUMEN

The degree of antigen adsorption to adjuvants in subunit vaccines may significantly influence the immune responses they induce upon vaccination. Commonly used approaches for studying how the level of adsorption affects the induction of antigen-specific immune responses include (i) using adjuvants with different abilities to adsorb antigens, and (ii) comparing different antigens selected based on their ability to adsorb to the adjuvant. A weakness of these approaches is that not only the antigen adsorption level is varied, but also other important functional factors such as adjuvant composition and/or the B/T cell epitopes, which may affect immunogenicity. Hence, we investigated how changing the adsorption capabilities of a single antigen to an adjuvant influenced the vaccine-induced immune responses. The model antigen lysozyme, which displays a positive net charge at physiological pH due to an isoelectric point (pI) of 11, was succinylated to different extents, resulting in a reduction of the pI value to 4.4-5.9, depending on the degree of succinylation. A pronounced inverse correlation was found between the pI value of the succinylated lysozyme analogues and the degree of adsorption to a cationic liposomal adjuvant consisting of dimethyldioctadecylammonium bromide (DDA) and trehalose dibehenate (TDB) (CAF®01). Furthermore, increased adsorption to this adjuvant correlated directly with the magnitude of lysozyme-specific Th1/Th17 immune responses induced by the vaccine in mice, while there was an inverse correlation with antibody induction. However, high lysozyme-specific antibody titers were induced with an increased antigen dose, even upon vaccination with a strongly adsorbed succinylated lysozyme analogue. Hence, these data illustrate that the degree of lysozyme adsorption to CAF®01 strongly affects the quality of the resulting immune responses.


Asunto(s)
Adyuvantes Inmunológicos/química , Antígenos/inmunología , Vacunas de Subunidad/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Adsorción , Animales , Antígenos/administración & dosificación , Antígenos/química , Cationes/administración & dosificación , Cationes/química , Femenino , Glucolípidos/administración & dosificación , Glucolípidos/química , Inmunogenicidad Vacunal , Liposomas , Ratones , Modelos Animales , Muramidasa/administración & dosificación , Muramidasa/química , Muramidasa/inmunología , Compuestos de Amonio Cuaternario/administración & dosificación , Compuestos de Amonio Cuaternario/química , Células TH1 , Células Th17 , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/química
11.
Nutrients ; 13(4)2021 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-33920187

RESUMEN

Various proteins or protein fractions reportedly positively affect gastrointestinal integrity and inflammation in diets providing >45% energy as fat. This study tested whether benefits were seen in diets providing 30% of energy as fat. Purified diets (PD) with isolated soy protein (ISP), dried whole milk powder (DWMP), milk fat globule membrane (MFGM), or milk protein concentrate (MPC) as protein sources were fed to C57BL/6J mice (n = 15/diet group) for 13 weeks. MFGM-fed mice were heaviest (p < 0.005) but remained within breeder norms. Growth rates and gut motility were similar for all PD-fed mice. FITC-dextran assessed gut permeability was lowest in DWMP and MFGM (p = 0.054); overall, plasma endotoxin and unprovoked circulating cytokines indicated a non-inflammatory state for all PD-fed mice. Despite differences in cecal butyrate and intestinal gene expression, all PDs supported gastrointestinal health. Whole milk provided more positive effects compared to its fractions. However, ISP-fed mice showed a >370%, (p < 0.006) increase in colonic myeloperoxidase activity indicative of tissue neutrophil infiltration. Surprisingly, FITC-dextran and endotoxin outcomes were many folds better in PD-fed mice than mice (strain, vendor, age and sex matched) fed a "chow-type" nutritionally adequate non-PD. Additional variables within a diet's matrix appear to affect routine indicators or gastrointestinal health.


Asunto(s)
Conducta Alimentaria/fisiología , Tracto Gastrointestinal/fisiología , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Proteínas de la Leche/administración & dosificación , Proteínas de Soja/administración & dosificación , Alimentación Animal , Animales , Biomarcadores , Motilidad Gastrointestinal , Gotas Lipídicas , Masculino , Ratones , Ratones Endogámicos C57BL , Modelos Animales
12.
Nutrients ; 13(3)2021 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-33668227

RESUMEN

(1) Background: Milk fat globule membrane (MFGM), composing fat droplets responsible for lipid transport in breast milk, has been shown to possess immunological and antimicrobial effects. Standard formulas (SF) are devoid of MFGMs during the production process. The study's aim was to evaluate the safety and benefits of MFGMs supplementation in children. (2) Methods: We searched four databases for randomized controlled trials evaluating the supplementation of MFGMs in children. Growth parameters were chosen as the primary outcome. (3) Results: Twenty-four publications of seventeen studies were included. Meta-analyses assessing the primary outcomes at the age of 4 months included four studies (814 children) comparing the MFGM-supplemented formulas and SF, and two trials (549 children) comparing the MFGM-supplemented formulas and breastfeeding. The primary outcomes were non-inferior in all the experimental MFGM formulas compared to SF, or even represented more similar results to breastfed infants. The promising effects, including a lower incidence of acute otitis media and improved cognitive development, cannot be firmly confirmed due to the small amount of existing evidence. No significant adverse effects were reported in any of the assessed products. (4) Conclusions: The available data signaled beneficial effects and a good safety profile, requiring future research with well-designed trials.


Asunto(s)
Desarrollo Infantil/efectos de los fármacos , Cognición/efectos de los fármacos , Suplementos Dietéticos , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Fórmulas Infantiles/química , Lactancia Materna , Femenino , Humanos , Lactante , Gotas Lipídicas , Masculino , Leche Humana/química , Ensayos Clínicos Controlados Aleatorios como Asunto
13.
J Nutr ; 151(6): 1487-1496, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-33693864

RESUMEN

BACKGROUND: Exposure to a maternal high-fat diet (HFD) predisposes offspring to nonalcoholic fatty liver disease. OBJECTIVES: The aim of this study was to explore whether milk fat globule membrane (MFGM) supplementation during suckling exerts a long-term protective effect on hepatic lipid metabolism in adult offspring exposed to maternal HFD. METHODS: We fed 5-week-old female C57BL/6J mice either a HFD (60% kcal fat) or control diet (CD; 16.7% kcal fat) for 3 weeks before mating, as well as throughout gestation and lactation. After delivery, male offspring from HFD dams were supplemented with 1 g/(kg body weight·day) MFGM (HFD + MFGM group) or the same volume of vehicle (HFD group) during suckling. Male offspring from CD dams were also supplemented with vehicle during suckling (CD group). All offspring were weaned onto CD for 8 weeks. Histopathology, metabolic parameters, lipogenic level, oxidative stress, and mitochondria function in the liver were analyzed. A 1-way ANOVA and a Kruskal-Wallis test were used for multi-group comparisons. RESULTS: As compared to the CD group, the HFD group had more lipid droplets in livers, and exhibited ∼100% higher serum triglycerides, ∼38% higher hepatic triglycerides, ∼75% higher serum aspartate aminotransferase, and ∼130% higher fasting blood glucose (P < 0.05). The changes of these metabolic parameters were normalized in the HFD + MFGM group. Phosphorylated mammalian targets of rapamycin and AKT were downregulated, but phosphorylated adenosine monophosphate-activated protein kinase was upregulated in the HFD + MFGM group as compared to the HFD group (P < 0.05). As compared to the CD group, the HFD group showed an ∼80% higher malondialdehyde level, and ∼20% lower superoxide dismutase activity (P < 0.05), which were normalized in the HFD + MFGM group. Additionally, mitochondria function was also impaired in the HFD group and normalized in the HFD + MFGM group. CONCLUSIONS: MFGM supplementation during suckling ameliorates maternal HFD-induced hepatic steatosis in mice via suppressing de novo lipogenesis, reinforcing antioxidant defenses and improving mitochondrial function.


Asunto(s)
Dieta Alta en Grasa , Hígado Graso/prevención & control , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Fenómenos Fisiologicos Nutricionales Maternos , Animales , Aspartato Aminotransferasas/sangre , Glucemia , Dieta Alta en Grasa/efectos adversos , Suplementos Dietéticos , Femenino , Gotas Lipídicas , Hígado , Masculino , Ratones , Ratones Endogámicos C57BL , Triglicéridos/análisis
14.
PLoS One ; 16(2): e0244916, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33626041

RESUMEN

BACKGROUND: Gangliosides are a class of sphingolipids that are present in the cell membranes of vertebrates. Gangliosides influence a broad range of cellular processes through effects on signal transduction, being found abundantly in the brain, and having a role in neurodevelopment. OBJECTIVE: We aimed to assess the effects of maternal daily consumption of ganglioside-enriched milk vs non-enriched milk and a non-supplemented group of pregnant women on maternal ganglioside levels and pregnancy outcomes. DESIGN: Double-blind parallel randomized controlled trial. METHODS: 1,500 women aged 20-40 years were recruited in Chongqing (China) between 11 and 14 weeks of a singleton pregnancy, and randomized into three groups: Control-received standard powdered milk formulation (≥4 mg gangliosides/day); Complex milk lipid-enhanced (CML-E) group-same formulation enriched with complex milk lipids (≥8 mg gangliosides/day) from milk fat globule membrane; Reference-received no milk. Serum ganglioside levels were measured in a randomly selected subsample of 250 women per group. RESULTS: CML-E milk was associated with marginally greater total gangliosides levels in maternal serum compared to Control (13.02 vs 12.69 µg/ml; p = 0.034) but not to Reference group. CML-E milk did not affect cord blood ganglioside levels. Among the 1500 women, CML-E milk consumption was associated with a lower rate of gestational diabetes mellitus than control milk [relative risk 0.80 (95% CI 0.64, 0.99)], but which was not different to the Reference group. CML-E milk supplementation had no other effects on maternal or newborn health. CONCLUSIONS: Maternal supplementation with milk fat globule membrane, as a source of gangliosides, was not associated with any adverse health outcomes, and did not increase serum gangliosides compared with the non-supplemented reference group. TRIAL REGISTRATION: Chinese Clinical Trial Register (ChiCTR-IOR-16007700). CLINICAL TRIAL REGISTRATION: ChiCTR-IOR-16007700; www.chictr.org.cn/showprojen.aspx?proj=12972.


Asunto(s)
Gangliósidos/administración & dosificación , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Leche , Adulto , Animales , Pueblo Asiatico , Encéfalo/metabolismo , Cognición/efectos de los fármacos , Suplementos Dietéticos , Método Doble Ciego , Femenino , Glucolípidos/metabolismo , Glicoproteínas/metabolismo , Humanos , Gotas Lipídicas/metabolismo , Embarazo
15.
Poult Sci ; 100(2): 810-819, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33518135

RESUMEN

This study determined the effects of dietary supplementation of rhamnolipids (RLS) on the growth performance, gut morphology, immune function, intestinal volatile fatty acid, and microflora community in Linnan yellow broilers. A total of 480 1-day-old broiler chicks were randomly assigned to groups for supplementation with one of the following for 56 d: no supplement (control), 30 mg/kg bacitracin (ANT), 500 mg/kg RLS, or 1,000 mg/kg RLS (RLS2). The RLS2 diet was found to improve the final BW and ADG on day 56. The RLS diet reduced jejunal crypt depth, increased jejunal villus length, and increased serum IgA, IgM, IgY, IL-1ß, IL-6, and tumor necrosis factor-alpha (TNF-α) levels. The RLS broilers had higher cecum concentrations of acetic acid, propionic acid, butyrate, isobutyric acid, valerate, and isovalerate. High-throughput sequencing indicated that RLS affected microbial quantity and diversity in the cecum. Bacterial richness was higher in the RLS broilers than the ANT broilers. The RLS broilers had higher relative abundances of Megasphaera hypermegale and Lachnospiraceae bacterium 19gly4 on day 28 and Clostridium spiroforme and Alistipes obesi on day 56. These results suggest that RLS supplementation improves growth performance, benefits the intestinal villus morphology, regulates host immune function, and raises intestinal volatile fatty acid content and the relative abundance of the gut microbiota in broiler chickens.


Asunto(s)
Alimentación Animal , Pollos , Glucolípidos/administración & dosificación , Intestinos/fisiología , Alimentación Animal/análisis , Animales , Bacteroidetes/crecimiento & desarrollo , Pollos/clasificación , Pollos/crecimiento & desarrollo , Pollos/fisiología , Dieta/veterinaria , Suplementos Dietéticos , Firmicutes/crecimiento & desarrollo , Intestinos/crecimiento & desarrollo , Intestinos/microbiología , Distribución Aleatoria
16.
Am J Clin Nutr ; 113(3): 586-592, 2021 03 11.
Artículo en Inglés | MEDLINE | ID: mdl-33564853

RESUMEN

BACKGROUND: We previously reported results from a randomized controlled trial in which we found that Swedish infants consuming an experimental low-energy, low-protein formula (EF) supplemented with bovine milk fat globule membranes (MFGMs) until 6 mo of age had several positive outcomes, including better performance in the cognitive domain of Bayley Scales of Infant and Toddler Development 3rd Edition at 12 mo of age, and higher plasma cholesterol concentrations during the intervention, than infants consuming standard formula (SF). OBJECTIVES: We aimed to evaluate neurodevelopment, growth, and plasma cholesterol status at 6 and 6.5 y of age in the same study population. METHODS: We assessed cognitive and executive functions using the Wechsler Intelligence Scale for Children 4th Edition (WISC-IV), Brown Attention-Deficit Disorder Scales for Children and Adolescents (Brown-ADD), and Quantified Behavior (Qb) tests, and behavior using the Child Behavior Checklist (CBCL) and Teacher's Report Form (TRF), at 6.5 y of age. Anthropometrics and plasma lipids were assessed at 6 y of age. RESULTS: There were no differences between the EF and SF groups in any of the subscales in WISC-IV or Brown-ADD at 6.5 y of age, in the proportion of children with scores outside the normal range in the Qb test, nor in clinical or borderline indications of problems in adaptive functioning from parental and teacher's scoring using the CBCL and TRF. There were no differences between the EF and SF groups in weight, length, or head or abdominal circumferences, nor in plasma concentrations of homocysteine, lipids, insulin, or glucose. CONCLUSIONS: Among children who as infants consumed a low-energy, low-protein formula supplemented with bovine MFGMs, there were no effects on neurodevelopment, growth, or plasma cholesterol status 6-6.5 y later.


Asunto(s)
Desarrollo Infantil , Dieta con Restricción de Proteínas , Suplementos Dietéticos , Ingestión de Energía , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Fórmulas Infantiles , Animales , Bovinos , Niño , Femenino , Estudios de Seguimiento , Humanos , Gotas Lipídicas , Masculino , Neurogénesis
17.
Cells ; 10(2)2021 01 27.
Artículo en Inglés | MEDLINE | ID: mdl-33513913

RESUMEN

Fabry disease is a lysosomal storage disease with an X-linked heritage caused by absent or decreased activity of lysosomal enzymes named alpha-galactosidase A (α-gal A). Among the various manifestations of Fabry disease, Fabry nephropathy significantly affects patients' morbidity and mortality. The cellular mechanisms of kidney damage have not been elusively described. Necroptosis is one of the programmed necrotic cell death pathways and is known to play many important roles in kidney injury. We investigated whether RIPK3, a protein phosphokinase with an important role in necroptosis, played a crucial role in the pathogenesis of Fabry nephropathy both in vitro and in vivo. The cell viability of podocytes decreased after lyso-Gb3 treatment in a dose-dependent manner, with increasing RIPK3 expression. Increased reactive oxygen species (ROS) generation after lyso-Gb3 treatment, which was alleviated by GSK'872 (a RIPK3 inhibitor), suggested a role of oxidative stress via a RIPK3-dependent pathway. Cytoskeleton rearrangement induced by lyso-Gb3 was normalized by the RIPK3 inhibitor. When mice were injected with lyso-Gb3, increased urine albuminuria, decreased podocyte counts in the glomeruli, and effaced foot processes were observed. Our results showed that lyso-Gb3 initiated albuminuria, a clinical manifestation of Fabry nephropathy, by podocyte loss and subsequent foot process effacement. These findings suggest a novel pathway in Fabry nephropathy.


Asunto(s)
Glucolípidos/farmacología , Podocitos/metabolismo , Podocitos/patología , Proteína Serina-Treonina Quinasas de Interacción con Receptores/metabolismo , Esfingolípidos/farmacología , Animales , Muerte Celular/efectos de los fármacos , Citoesqueleto/efectos de los fármacos , Citoesqueleto/metabolismo , Femenino , Glucolípidos/administración & dosificación , Inyecciones Intraperitoneales , Ratones Endogámicos C57BL , Modelos Biológicos , Podocitos/efectos de los fármacos , Podocitos/ultraestructura , Especies Reactivas de Oxígeno/metabolismo , Esfingolípidos/administración & dosificación
18.
Nutrients ; 12(12)2020 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-33333767

RESUMEN

Although early life nutrition influences brain development and mental health, the long-term effects of supplemented infant formula on children´s behavior remain unclear. We analyzed the effects of a bioactive nutrients-enriched-infant formula on children's behavior up to 2.5 years, compared to a standard infant formula or breastfeeding. Current analysis involved 70 children who were fed a standard infant formula (SF, n = 29) or a bioactive compounds enriched-infant formula (EF, n = 41), during their first 18 months of life, and 33 breastfed (BF) children (reference group) participating in the COGNIS study. Behavioral problems were evaluated using the Child Behavior Checklist at 18 months and 2.5 years. Different statistical analyses were performed using SPSS. EF children aged 2.5 years presented fewer pathological affective problems than SF children. Besides, SF children were classified more frequently as bordering on internalizing problems than BF children. Rates of externalizing problems were increased in SF infants compared to EF and BF infants. Higher maternal IQ was found to have beneficial effects on internalizing and total problem rate in their offspring at 18 months of life; finally, higher maternal educational level was related with fewer ADHD problems in children at 18 months, as well as internalizing, externalizing, total and anxiety problems in children aged 2.5 years. Our analysis suggests that enriched infant formula fed infants seem to show fewer behavioral problems up to 2.5 years compared to a standard infant formula-fed infants. In addition to type of early feeding, maternal IQ and educational level seem to play a key role on children behavioral development.


Asunto(s)
Ácidos Grasos Insaturados/administración & dosificación , Glucolípidos/administración & dosificación , Glicoproteínas/administración & dosificación , Fórmulas Infantiles/química , Fenómenos Fisiológicos Nutricionales del Lactante/efectos de los fármacos , Simbióticos/administración & dosificación , Lactancia Materna , Conducta Infantil/efectos de los fármacos , Desarrollo Infantil/efectos de los fármacos , Preescolar , Método Doble Ciego , Femenino , Alimentos Fortificados , Humanos , Lactante , Recién Nacido , Gotas Lipídicas , Masculino , Trastornos del Neurodesarrollo/etiología , Trastornos del Neurodesarrollo/prevención & control , Estudios Prospectivos
19.
Anim Sci J ; 91(1): e13464, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33021004

RESUMEN

Methyl-mannosylerythritol lipid (MEL), a new sugar esterified lipid synthesized by Pseudozyma aphidis, was assessed for its functionality in modulating rumen fermentation and microbiota toward more propionate and less methane production. A pure culture study using rumen representatives showed that MEL selectively inhibited the growth of most Gram-positive bacteria including Streptococcus bovis, ruminococci, and Fibrobacter succinogenes, but not Gram-negative bacteria such as Megasphaera elsdenii, Succinivibrio dextrinosolvens, and Selenomonas ruminantium. A batch culture study revealed that MEL significantly decreased methane production in a dose-dependent manner with accumulation of hydrogen, while propionate production was enhanced. A continuous culture (Rusitec) study confirmed all of these changes. A feeding study revealed that sheep fed a MEL diet showed an increased proportion of propionate, while proportions of acetate and butyrate were decreased without affecting total VFA level. These changes disappeared after cessation of MEL feeding. Based on these results, dietary application of MEL can favorably modify rumen fermentation in terms of the efficiency of dietary energy utilization.


Asunto(s)
Alimentación Animal , Antibacterianos , Dieta/veterinaria , Suplementos Dietéticos , Fermentación/efectos de los fármacos , Glucolípidos/administración & dosificación , Glucolípidos/farmacología , Bacterias Grampositivas/crecimiento & desarrollo , Rumen/metabolismo , Rumen/microbiología , Tensoactivos/farmacología , Animales , Relación Dosis-Respuesta a Droga , Metabolismo Energético , Masculino , Metano/metabolismo , Propionatos/metabolismo , Ovinos
20.
Mol Nutr Food Res ; 64(21): e2000232, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32918844

RESUMEN

SCOPE: Milk fat globule membrane (MFGM), which contains abundant polar lipids and glycoproteins, can narrow the gap in growth and development between breast-fed and infant-formula-fed babies. The objective of this study is to evaluate the effect of MFGM supplementation in infant formula on intestinal epithelium maturation, tight junctions, and gut colonization in rat pups. METHODS AND RESULTS: Sprague Dawley rat pups consume one of the five diets from postnatal day 8, including rat breastfeeding (BF), infant formula (IF), and infant formula containing MFGM at 260 mg kg-1 body weight (BW), 520 mg kg-1 BW, or 1040 mg kg-1 BW. Results show that MFGM supplementation in infant formula can facilitate intestinal mucosal barrier maturation via promoting intestinal proliferation and differentiation, and increasing tight junction proteins. In addition, compared with that of the IF pups, the intestinal flora composition of MFGM-supplemented pups is more similar to that of BF pups. CONCLUSION: MFGM supplementation in infant formula can restore the intestinal development in infant-formula-fed pups, which suggests that the supplementation of MFGM in infant formula can better mimic breast milk.


Asunto(s)
Microbioma Gastrointestinal/efectos de los fármacos , Glucolípidos/farmacología , Glicoproteínas/farmacología , Mucosa Intestinal/efectos de los fármacos , Animales , Animales Recién Nacidos , Peso Corporal/efectos de los fármacos , Suplementos Dietéticos , Microbioma Gastrointestinal/fisiología , Glucolípidos/administración & dosificación , Glucolípidos/química , Glicoproteínas/administración & dosificación , Glicoproteínas/química , Humanos , Lactante , Fórmulas Infantiles , Mucosa Intestinal/fisiología , Gotas Lipídicas/química , Ratas Sprague-Dawley , Bazo/efectos de los fármacos , Proteínas de Uniones Estrechas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...